News

A 50-year-old woman developed cold agglutinin disease (CAD) secondary to two different types of cancer within the thyroid gland, a study reported. The surgical removal of the thyroid gland successfully treated both the cancer and CAD. While CAD has been reported to occur secondary to blood cancers, it is…

A woman in Costa Rica developed cold agglutinin disease (CAD) secondary to a diagnosis of systemic lupus erythematosus (SLE) that was complicated by nephritis, a serious kidney inflammation that often occurs with this form of lupus. CAD “is exceptionally rare in SLE, with few cases being reported in…

Managing the life-threatening consequences of a rare autoimmune condition called ANCA-associated vasculitis (AAV) can be particularly challenging when cold agglutinin disease (CAD) is also present, according to a recent case report. In this first documented case of AAV co-occurring with CAD, scientists described how the cold temperature of…

Enjaymo (sutimlimab) was effective at controlling signs and symptoms of cold agglutinin disease (CAD) in a man in his 70s being given dialysis for kidney failure, a study in Japan reports. “To the best of our knowledge, this is the first report of CAD in a patient undergoing…

Long-term treatment with Enjaymo (sutimlimab) leads to sustained reductions in red blood cell destruction, anemia, and fatigue, as well as life quality improvements, in adults with cold agglutinin disease (CAD). That’s according to data from the extension portion (Part B) of the global Phase 3 CADENZA clinical…

A Japanese woman developed cold agglutination disease (CAD) following COVID-19 and a secondary bacterial infection in the lungs that may have worsened her symptoms, a case study showed. “There is a need for continuous observation to evaluate whether COVID-19, even when it does not require hospitalization, is related to…

Distinguishing between primary and secondary cold agglutinin disease (CAD), as well as understanding if cancer is the underlying cause of secondary CAD, is critical to ensure patients get the right treatment, according to a recent review study. Primary CAD — sometimes known simply as CAD — is not…

Decisions about cold agglutinin disease (CAD) treatment need to be made on a case-by-case basis, considering each patient’s specific situation, a pair of scientists in Italy argued in a review study. The scientists reviewed available and up-and coming treatment options for CAD, giving advice for how best to employ…

Obinutuzumab, a B cell-depleting medication approved for certain blood cancers, was effective for controlling primary cold agglutinin disease (CAD) in a woman in China, according to a case study. The treatment “shows a promising role in CAD which might [warrant] further investigation,” researchers wrote in the case study, “…

Enjaymo (sutimlimab), the only approved treatment for cold agglutinin disease (CAD), needs to be about 80% cheaper or be used for a maximum limit of 1.5 years to meet conventional thresholds for cost-effectiveness in the U.S. That’s according to a cost-effectiveness analysis that was based on data from…